They also uncover novel mechanisms elicited by AT-SPM in regulating both innate and adaptive immune responses during I-CRC that may be applicable to other cancers where PD-1 plays a central role in disease onset and/or progression, thereby the present findings supporting the utility of SPM-based therapeutics in both cancer prevention and treatment. This evidence concerns the gene PDCD1 and colorectal carcinoma.